Literature DB >> 8640722

The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas.

D Chou1, T Miyashita, H W Mohrenweiser, K Ueki, K Kastury, T Druck, A von Deimling, K Huebner, J C Reed, D N Louis.   

Abstract

The bax protein regulates apoptosis in a cellular pathway that involves both bcl-2 and p53, two molecules associated with human glioma tumorigenesis. We therefore evaluated the possibility that BAX functions as a glioma tumor suppressor gene. Somatic cell hybrid panels, fluorescence in situ hybridization and cosmid mapping localized the BAX gene to 19q13.3, approximately 300 kb centromeric to HRC. Thus BAX maps to the region of chromosome 19 most frequently deleted in gliomas. Routine and pulsed-field gel electrophoresis/Southern blotting studies, however, failed to reveal large-scale deletions or rearrangements of the BAX gene in gliomas. In addition, single strand conformation polymorphism analysis of all six BAX exons and flanking intronic sequences did not disclose mutations in 20 gliomas with allelic loss of the other copy of 19q. A C/T polymorphism was detected in intron 3 and was common in the general population. Therefore, although BAX maps to the glioma candidate region on the long arm of chromosome 19, BAX is probably not the 19q glioma tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640722     DOI: 10.1016/0165-4608(95)00341-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  Diamond-Blackfan anaemia in a girl with a de novo balanced reciprocal X;19 translocation.

Authors:  P Gustavsson; G Skeppner; B Johansson; T Berg; L Gordon; A Kreuger; N Dahl
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

2.  Loss of BCL-2 in the progression of oral cancer is not attributable to mutations.

Authors:  L L Loro; A C Johannessen; O K Vintermyr
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

3.  BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.

Authors:  Richard A Lytle; Zhihong Jiang; Xiao Zheng; Keith M Rich
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

Review 4.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

5.  Microsatellite instability and mutation of DNA mismatch repair genes in gliomas.

Authors:  S Y Leung; T L Chan; L P Chung; A S Chan; Y W Fan; K N Hung; W K Kwong; J W Ho; S T Yuen
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

6.  Downregulation of miR-217 correlates with resistance of Ph(+) leukemia cells to ABL tyrosine kinase inhibitors.

Authors:  Chie Nishioka; Takayuki Ikezoe; Jing Yang; Atsuya Nobumoto; Masayuki Tsuda; Akihito Yokoyama
Journal:  Cancer Sci       Date:  2014-01-30       Impact factor: 6.716

7.  Abnormal intracellular localization of Bax with a normal membrane anchor domain in human lung cancer cell lines.

Authors:  A Salah-eldin; S Inoue; M Tsuda; A Matsuura
Journal:  Jpn J Cancer Res       Date:  2000-12

8.  Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors.

Authors:  Natássia C R Corrêa; Hellen Kuasne; Jerusa A Q A Faria; Ciça C S Seixas; Iria G D Santos; Francine B Abreu; Suely Nonogaki; Rafael M Rocha; Gerluza Aparecida Borges Silva; Helenice Gobbi; Silvia R Rogatto; Alfredo M Goes; Dawidson A Gomes
Journal:  Oncol Rep       Date:  2013-02-12       Impact factor: 3.906

9.  Lack of association between Bax promoter (-248G>A) single nucleotide polymorphism and susceptibility towards cancer: evidence from a meta-analysis.

Authors:  Sushil Kumar Sahu; Tathagata Choudhuri
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

10.  Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.

Authors:  Yu Peng; Linang Wang; Yi Qing; Chongyi Li; Tao Ren; Qing Li; Mengxia Li; Shiheng Zhang; Jinglu Shan; Ge Wang; Zhenzhou Yang; Dong Wang
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.